Commentary

What the National Psoriasis Foundation Means to Dermatologists and Our Patients [letter]

Cutis. 2008 September;82(3):181-183
By
Kaufman ED
Lebwohl MG
Krueger GG
Zimmerman G
Feldman SR

Kaufman ED, Lebwohl MG, Krueger GG, Zimmerman G, Feldman SR

No abstract available.
PDF Download

 

Recommended Reading

Minocycline Joins List of Lupus-Inducing Drugs
Psoriasis Collection
Bullous Pemphigoid Managed With Methotrexate
Psoriasis Collection
Autoantibodies for Bullous Pemphigoid Found in Unaffected
Psoriasis Collection
Bullous Pemphigoid and Pemphigus Vulgaris Rates Climbing in U.K.
Psoriasis Collection
Vitamin D, Estrogen May Be Key to New SLE Tx
Psoriasis Collection
Autoimmune Testing Helps Guide Urticaria Tx
Psoriasis Collection
Prevalence of Mood and Sleep Problems in Chronic Skin Diseases: A Pilot Study
Psoriasis Collection
A Single-Center, Double-Blind, Randomized Trial of the Atrophogenic Effects of Fluocinonide Cream 0.1% Versus Clobetasol Propionate Cream 0.05% in Participants With Corticosteroid-Responsive Dermatoses
Psoriasis Collection
A New Standardized Method of Evaluating Cutaneous Irritation From Topical Medications
Psoriasis Collection
Psoriasis in the Patient With Human Immunodeficiency Virus, Part 1: Review of Pathogenesis
Psoriasis Collection